Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study - Summary - MDSpire

Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study

  • By

  • Bing Liu

  • Ye Tao

  • Minglei Zhuo

  • Li-Di Xu

  • Xueyan Cheng

  • Wei Tao

  • Zhangdong Xie

  • Chao Lv

  • Yuzhao Wang

  • Shaolei Li

  • Shanyuan Zhang

  • Miao Huang

  • Yaqi Wang

  • Xiang Li

  • Yuge Zhu

  • Xinrui Cui

  • Xuantong Zhou

  • Bateer Han

  • Enli Zhang

  • Yu S. Huang

  • Weizhi Chen

  • Jia Wang

  • Shi Yan

  • Nan Wu

  • November 5, 2025

  • 0 min

Share

Objective:

To investigate the efficacy and safety of neoadjuvant toripalimab plus chemotherapy in resectable stage IIB-IIIB NSCLC and explore the association of cfDNA features with pathological response, specifically focusing on predictive outcomes.

Key Findings:
  • cfDNA methylation features showed potential as predictive biomarkers for neoadjuvant chemoimmunotherapy, validated through statistical analysis.
  • Integrated models combining cfDNA features and immune parameters improved prediction of pathological response, demonstrating enhanced accuracy.
Interpretation:

The study suggests that cfDNA methylation monitoring may enhance the predictive accuracy for treatment outcomes in NSCLC patients undergoing neoadjuvant therapy.

Limitations:
  • Single-center study may limit generalizability and introduce biases.
  • Small sample size may affect the robustness of findings and limit statistical power.
Conclusion:

cfDNA methylation patterns could serve as valuable predictive biomarkers for neoadjuvant treatment response in NSCLC, warranting further investigation and consideration in clinical practice.

Original Source(s)

Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study

  • by Bing Liu, Ye Tao, Minglei Zhuo, Li-Di Xu, Xueyan Cheng, Wei Tao, Zhangdong Xie, Chao Lv, Yuzhao Wang, Shaolei Li, Shanyuan Zhang, Miao Huang, Yaqi Wang, Xiang Li, Yuge Zhu, Xinrui Cui, Xuantong Zhou, Bateer Han, Enli Zhang, Yu S. Huang, Weizhi Chen, Jia Wang, Shi Yan, Nan Wu

  • November 5, 2025

Related Content

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation